MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

Simulations Plus Inc

Suletud

SektorTervishoid

14.27 1.64

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

14.18

Max

14.64

Põhinäitajad

By Trading Economics

Sissetulek

3.9M

4.5M

Müük

5.9M

24M

Aktsiakasum

0.35

Dividenditootlus

0.48

Kasumimarginaal

18.669

Töötajad

212

EBITDA

4.9M

7.2M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+66.43% upside

Dividendid

By Dow Jones

Dividenditootlus

Sektori keskmine

0.48%

2.38%

Järgmine tulemuste avaldamine

13. juuli 2026

Turustatistika

By TradingEconomics

Turukapital

11M

262M

Eelmine avamishind

12.63

Eelmine sulgemishind

14.27

Uudiste sentiment

By Acuity

13%

87%

19 / 348 Pingereas Healthcare

Simulations Plus Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

17. apr 2026, 20:26 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15 Billion

17. apr 2026, 18:15 UTC

Uudisväärsed sündmused

Fed's Waller: Prolonged Iran Conflict Could Block Path to Rate Cuts

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI -2-

17. apr 2026, 16:49 UTC

Uudisväärsed sündmused

Week Ahead for FX, Bonds: U.S. Retail Sales, PMI Data Due as Focus Remains on Middle East

17. apr 2026, 22:58 UTC

Tulu

Grupo Aeroportuario Del Pacifico: Announces Filing of 2025 Annual Report and Form 20-F

17. apr 2026, 21:32 UTC

Market Talk

Cerebras IPO Adds to Big Year For AI Firms Going Public -- Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17. apr 2026, 21:22 UTC

Market Talk

Moody's Downgrades Belgium to A1 -- Market Talk

17. apr 2026, 20:52 UTC

Tulu

Schwab Investors Get Spooked by JPMorgan's AI Strategy. The Big Worry Is Cash Sweeps. -- Barrons.com

17. apr 2026, 20:50 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

17. apr 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17. apr 2026, 20:29 UTC

Tulu

These Stocks Are Today's Movers: Royal Caribbean, Dow Inc., Netflix, Intel, Albemarle, Autoliv, Alcoa, and More -- Barrons.com

17. apr 2026, 20:11 UTC

Omandamised, ülevõtmised, äriostud

UCB to Buy Neurona Therapeutics for Up to $1.15B

17. apr 2026, 19:34 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Global Equities Roundup: Market Talk

17. apr 2026, 19:34 UTC

Market Talk
Tulu
Omandamised, ülevõtmised, äriostud

Analysts See Netflix's Deal Commentary as Notable -- Market Talk

17. apr 2026, 19:31 UTC

Market Talk
Uudisväärsed sündmused

Oil Futures Fall on Reopening of Strait of Hormuz -- Market Talk

17. apr 2026, 19:26 UTC

Market Talk

U.S. Natural Gas Futures Edge Up -- Market Talk

17. apr 2026, 19:21 UTC

Market Talk

Albemarle's Outperformance Belies Longer-Term Risks -- Market Talk

17. apr 2026, 19:15 UTC

Market Talk

Danaher Seen Rebounding in 2H After Tools-Sector Weakness -- Market Talk

17. apr 2026, 19:07 UTC

Market Talk

Danaher Faces Tough Comparative but Long‑Term Story Intact -- Market Talk

17. apr 2026, 18:57 UTC

Uudisväärsed sündmused

U.S. Stocks Surge on Hope Iran War Nearing End. Foreign Leaders Have a More Sober View. -- Barrons.com

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB Expects 2026 Adjusted Ebitda Growth in High Single-Digit to Mid-Teens Percentage Range at Constant Exchange Rates

17. apr 2026, 18:53 UTC

Omandamised, ülevõtmised, äriostud

UCB 2026 Rev Guidance Unchanged

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB: Neurona Deal to Include $650M Upfront and Up to $500M in Potential Future Milestones

17. apr 2026, 18:52 UTC

Omandamised, ülevõtmised, äriostud

UCB to Acquire Neurona Therapeutics for Up to $1.15B Including Potential Milestones

17. apr 2026, 18:14 UTC

Market Talk
Uudisväärsed sündmused

Precious Metals Close Higher as Stronger Demand Eyed -- Market Talk

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Quick Resolution in Middle East Could Allow Cuts Later This Year

17. apr 2026, 18:00 UTC

Uudisväärsed sündmused

Fed's Waller: Job Losses May Not Signal Recession Amid Demographic Changes

17. apr 2026, 17:31 UTC

Market Talk
Uudisväärsed sündmused

U.S. Oil Rig Count Down By 1 at 410 -- Market Talk

17. apr 2026, 17:26 UTC

Market Talk
Tulu

Netflix's Ability to Grow Engagement Seen as Up in the Air -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Simulations Plus Inc Prognoos

Hinnasiht

By TipRanks

66.43% tõus

12 kuu keskmine prognoos

Keskmine 23.5 USD  66.43%

Kõrge 31 USD

Madal 16 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Simulations Plus Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

4 ratings

2

Osta

2

Hoia

0

Müü

Sentiment

By Acuity

19 / 348 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat